Patients with type 2 diabetes currently using basal insulin, previously intensified with bolus or GLP-1 RA, or premixed insulin
| Patients with type 2 diabetes | Region | |||
|---|---|---|---|---|
| All regions | North America | South America | Europe | |
| Total number of respondents | 439 | 78 | 199 | 162 |
| Previously added bolus to basal insulin | ||||
| Number of patients | 235 (53.5%) | 41 (52.6%) | 115 (57.8%) | 79 (48.8%) |
| Reasons for going back to basal insulin only | ||||
| Difficult to handle multiple injections | 26.4% | 29.3% | 27.8% | 22.8% |
| Risk of weight gain | 25.1% | 39.0% | 17.4% | 29.1% |
| Risk of hypoglycemia events | 23.8% | 24.4% | 20.9% | 27.9% |
| Difficult to calculate bolus dose | 22.1% | 14.6% | 25.2% | 21.5% |
| Other reasons | 21.3% | 22.0% | 22.6% | 19.0% |
| Previously added GLP-1 RA to basal insulin | ||||
| Number of patients | 48 (10.9%) | 7 (9.0%) | 19 (9.5%) | 22 (13.6%) |
| Reasons for going back to basal insulin only | ||||
| Difficult to handle multiple injections | 29.2% | 42.9% | 31.6% | 22.7% |
| Risk of hypoglycemic events | 31.3% | 0.0% | 52.6% | 22.7% |
| Risk of gastrointestinal (GI) side effects | 18.8% | 0.0% | 26.3% | 18.2% |
| Other reasons | 31.3% | 57.1% | 10.5% | 40.9% |
| Previously switched to premixed insulin | ||||
| Number of patients | 156 (35.5%) | 30 (38.5%) | 65 (32.7%) | 61 (37.7%) |
| Reasons for going back to basal insulin only | ||||
| Difficult to handle multiple injections | 49.4% | 36.7% | 61.5% | 42.6% |
| Risk of weight gain | 34.6% | 26.7% | 27.7% | 45.9% |
| Risk of hypoglycemic events | 17.3% | 20.0% | 23.1% | 9.8% |
| Other reasons | 11.5% | 23.3% | 4.6% | 13.1% |
GLP-1 RA, glucagon-like peptide receptor antagonist.